Photo: Justin Sullivan / Getty Images
For: Real America News Updated 12 Feb 2022 , 19: 33 pm EST
Pfizer said it will wait for more data on a three-dose vaccine for children until April, when the data is expected to be available.
“Since the As the study proceeds at a rapid pace, the companies will await data from all three doses as Pfizer and BioNTech continue to believe it may provide a higher level of protection for this age group,” the companies announced in a statement.
Pfizer said the extension “allows the FDA time to receive data updated on the two- and three-dose regimen, conduct a thorough evaluation and facilitate a robust public discussion.”
Earlier this month, Pfizer said it expected the vaccine for children under 5 to get an emergency use authorization as soon as the end of February.
In the Pfizer trial initially enrolled 4,801 children ages 6 months to less than 12 years of 90 clinical centers in the United States, Finland, Poland and Spain.
In December, Pfizer reported that two doses of the vaccine did not give children 2 to 4 years of age sufficient immunity.
In light of the action of Pfizer and BioNTech, the FDA postponed an advisory committee meeting scheduled for next week to discuss Pfizer’s data on COVID vaccines-19 for small children.
Read more
Residents of vulnerable communities will be able to get vaccinated or receive a booster dose the day before the Super Bowl in InglewoodLong-term Covid: “I can’t drive far, I I forget to close doors, I burn the food…” – Real America News
Pfizer will request the FDA to authorize its Covid vaccine for children from 6 months to four years old